Compare Oscar Health Inc (OSCR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Oscar Health Inc trades at $28.23 (market cap $9.28B), while State Street SPDR S&P Biotech ETF trades at $151.92. Which is the better fit depends on your goals.
| OSCR | XBI | |
|---|---|---|
Market Cap | $9.28B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $32.18 | $164.28 |
52-Week Low | $10.85 | $85.16 |
Enterprise Value | $4.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.
The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
